Upon completion of this activity, learners will be better able to:
- Evaluate recent efficacy and safety data from pivotal trials assessing new and emerging therapies for MM
- Apply disease-specific and individual patient considerations to optimize personalized treatment planning in MM
- Assess the evolving evidence on using MRD assessments to guide the choice and duration of maintenance therapy
- Implement the latest best practices for preventing and managing treatment-related toxicities in patients with MM
Program Chair
Mohamad Mohty, MD, PhD
Professor of Hematology
Sorbonne University
Head, Clinical Hematology and Cellular Therapy Department
Saint-Antoine Hospital
Paris, France
Speaker
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, MN
Speaker
Suzanne Lentzsch, MD, PhD
Professor of Medicine at Columbia University
Director, Multiple Myeloma and Amyloidosis Service
Columbia University Irving Medical Center
New York, NY
Speaker
Philippe Moreau, MD
Professor of Clinical Hematology
University Hospital of Nantes, France
Nantes, France
| AGENDA | |
|---|---|
| 5 min | Faculty introductions, program overview, and pre-activity assessment questions |
| 15 min |
Medical Crossfire® Debate
|
| 15 min |
Medical Crossfire® Debate
|
| 15 min |
Medical Crossfire® Debate
|
| 15 min |
Panel Discussion
Future directions/new therapies: panel discussion touching on new MoAs and where we are going? |
| 10 min |
Post-activity assessment questions, faculty Q&A session, and concluding remarks
|
